The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
The British government is proposing legislative changes to allow troops to intercept and destroy threatening drones near defense sites, following a sharp increase in reported incidents amid heightened European security tensions.
American Airlines begins compensating flight attendants left without accommodations during Winter Storm Fern, as the union accuses management of contract violations and calls for accountability.
As Chinese exports, from electric vehicles to e-commerce goods, reshape Latin American markets, governments and industries grapple with the dual pressures of affordable consumer goods and strained local manufacturing, forcing a delicate recalibration of trade policies and regional alliances.
As the global payments giant prepares to report its fiscal year results, analysts forecast continued strong fundamentals for Visa. However, its recent underperformance against the broader market and a cautious consumer climate raise questions for investors seeking value.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
Newly released figures reveal a sharp 111% increase in unauthorized drone activity near UK defence sites in 2025, prompting an expansion of military powers to counter the aerial threat.
Bassett Furniture Industries (NASDAQ: BSET) has seen significant price swings in recent months, drawing investor scrutiny. With a current trading price well below its calculated intrinsic value and a bullish earnings forecast, analysts are debating whether this small-cap furniture maker presents a timely buying opportunity.
As major U.S. banks wrap up their fourth-quarter earnings, a clear divergence emerges. While PNC and Bank of America post strong results, Citigroup and JPMorgan Chase face headwinds. Truist Financial charts a middle course, meeting revenue expectations as the sector navigates a complex economic landscape.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Shares of Advantest Corp. have surged nearly 200% in the past year, riding the AI and advanced chipmaking wave. As the stock trades near record highs, investors are grappling with a critical question: has the rally run too far, too fast?
Fresenius SE & Co. KGaA (ETR:FRE) faces a challenging period as its stock declines, with a key profitability metric and a high dividend payout strategy raising questions about its near-term growth prospects.
